Barchart.com
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Cosciens Biopharma Inc (CSCI)

Cosciens Biopharma Inc (CSCI)
2.01 x 2 2.91 x 1
Post-market by (Cboe BZX)
2.85 +0.04 (+1.42%) 04/11/25 [NASDAQ]
2.01 x 2 2.91 x 1
Post-market 2.85 unch (unch) 10:34 ET
News & Headlines for Fri, Apr 11th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update GlobeNewswire - Wed Apr 9, 4:00PM CDT

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order GlobeNewswire - Tue Apr 1, 6:25PM CDT

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents Newsfile - Wed Mar 19, 6:42PM CDT

Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified...

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents GlobeNewswire - Wed Mar 19, 6:00PM CDT

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week Stocktwits - Sun Mar 16, 8:56PM CDT

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.4900 (+11.36%)
CSCI : 2.80 (-0.36%)
MLYS : 13.40 (+9.93%)
SWTX : 36.47 (+5.93%)
MGX : 1.4800 (+7.25%)
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product GlobeNewswire - Thu Mar 13, 6:55AM CDT

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization GlobeNewswire - Mon Dec 23, 2024

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs GlobeNewswire - Tue Nov 12, 2024

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)
COSCIENS Biopharma Announces Change to Board of Directors GlobeNewswire - Tue Oct 8, 2024

CSCI.TO : 4.01 (unch)
CSCI : 2.80 (-0.36%)

Barchart Exclusives

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? Barchart - 25 minutes ago
Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
UTC
Reserve Your Spot